# Dose Convenience: Oral and Long-Acting Quad-Agonists Following Retatrutide

Canonical source: https://retacompare.com/research/dose-convenience-oral-and-long-acting-quad-agonists-after-retatrutide

vs Retatrutide · 2026-05-02


    With the emergence of next-generation peptide therapies, the focus is shifting toward oral and long-acting quad-agonists that may enhance dosing convenience compared to Retatrutide, a triple agonist currently in Phase 3 trials.


The big picture

The landscape of obesity and metabolic disorder treatment is evolving rapidly, particularly in the wake of promising developments like Retatrutide, a GLP-1/GIP/glucagon triple agonist currently in Phase 3 clinical trials. As researchers explore additional combinations of receptor targeting, the next generation of multi-agonist therapies is anticipated to offer enhanced dosing convenience and potentially improved patient adherence. These advancements may include oral formulations and extended-release injections that could be administered monthly or even quarterly, thus addressing one of the significant challenges in chronic disease management: the frequency of dosing.


How it works

Multi-agonist therapies operate through a mechanism of action that targets multiple pathways involved in glucose metabolism, appetite regulation, and energy expenditure. Retatrutide, as a triple agonist, activates GLP-1, GIP, and glucagon receptors, each playing a distinct role in metabolic processes. GLP-1 and GIP are primarily involved in insulin secretion and appetite suppression, whereas glucagon contributes to energy mobilization. The rationale behind these combinations is to harness the synergistic effects of these pathways, potentially leading to greater efficacy in weight management and metabolic control.


Key points at a glance

Retatrutide is a GLP-1/GIP/glucagon triple agonist in Phase 3 trials.

Next-generation peptide therapies may include oral and long-acting formulations.

Quad-agonists are currently in preclinical or early clinical stages.

Notable candidates include HM15275 (Hanmi) and CT-388 (Roche/Carmot).

Oral formulations aim to enhance patient compliance by reducing injection frequency.

Combination therapies like CagriSema (cagrilintide + semaglutide) are also being explored.

All quad-agonist programs are preclinical or in early clinical stages with no approvals yet.


Where this fits in the pipeline

While Retatrutide is garnering attention as a triple agonist, several companies are advancing preclinical and early clinical programs for quad- and penta-agonist therapies. For instance, HM15275 from Hanmi is being investigated for its potential as a quad-agonist, while CT-388 from Roche/Carmot is also in early-stage development. These programs are still in the exploratory phases, with no clinical data publicly available yet to confirm their efficacy or safety profiles. The anticipated timelines for these candidates remain speculative, with ongoing research expected to shed light on their potential.


What it could mean for patients

The development of more convenient dosing regimens could significantly enhance patient adherence to obesity and metabolic disorder treatments. Oral formulations and long-acting injections may reduce the burden of frequent dosing, potentially leading to better management of weight and metabolic health. However, the clinical impact of these therapies will depend on their safety, efficacy, and tolerability, which are still under investigation. Early data from ongoing trials will be crucial in determining how these therapies compare to existing options like Tirzepatide and Semaglutide.


Open questions and what we don't yet know

Despite the excitement surrounding quad-agonist development, several uncertainties remain. Key questions include the long-term safety profiles of these therapies, their comparative efficacy against existing treatments, and the challenges of manufacturing and regulatory approval. Additionally, the biological interactions of multiple agonists within the body are complex and not yet fully understood, raising concerns about potential adverse effects. As these programs advance, further research will be necessary to address these gaps.


Bottom line

The future of obesity and metabolic disorder therapies appears promising, with the potential for more convenient dosing options on the horizon. However, as of now, no quad-agonist or penta-agonist has received regulatory approval.


This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources